High blood pressure in children and teenagers at risk of ADPKD
Official title: Family Study of Early Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
Run by King's College London · NCT07260071 · Data updated 2026-11-12
This project will use MRI, blood tests, arterial stiffness measures, and ambulatory blood pressure monitoring to see how common high blood pressure is in 12–17-year-olds who have a parent with ADPKD.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years to 17 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | King's College London Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | August 15, 2025 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT07260071 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 12–17-year-olds who can tolerate MRI and blood tests, have a parent with confirmed ADPKD, and (with parental consent where required) agree to genetic testing.
✕Probably not a fit
Patients aged 18 or older, those unwilling to undergo genetic testing or MRI, or those with comorbid conditions that confound results are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project recruits adolescents aged 12–17 with a parent who has clinically confirmed autosomal dominant polycystic kidney disease and combines MRI imaging with genetic testing to identify ADPKD. Participants undergo office and ambulatory blood pressure measurement, non-invasive arterial stiffness testing, cardiac and renal MRI, and a blood sample for genetics and biomarkers. The aim is to estimate the true prevalence of hypertension in a general population sample of at-risk young people rather than cases seen in specialist centers. Results will inform whether earlier screening and treatment of blood pressure in this group should be recommended.
Why it matters
Potential benefit: If successful, the project could uncover undiagnosed high blood pressure in at-risk adolescents and support earlier treatment to reduce long-term cardiovascular and kidney risk.
How similar studies have gone: Previous reports from specialist pediatric nephrology clinics have found hypertension in up to about 25% of adolescents with ADPKD, but population-based screening using MRI plus genetic confirmation is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 12 - 17 years at the time of consent * Able to tolerate the key study investigations (office blood pressure measurement, ambulatory blood pressure measurement, MRI and blood test) * Parent with confirmed clinical diagnosis of ADPKD * Parent (if child \<16 years) or both parent and young person (if \>=16 years) consents to genetic testing for ADPKD and demonstrates understanding of the implications of this. Exclusion Criteria: * 18 years or above at the time of study entry * Unable to tolerate key study investigations * Presence of associated co-morbidities which make it difficult to interpret results, including congenital cardiac anomalies and known TSC-PKD1 mutations * Unwilling to undergo genetic testing for ADPKD
Where it's running
-
Evelina London Children's Hospital
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Manish Sinha, PhD, MRCP (UK), MRCPCH — King's College London
- Study coordinator: Benjamin Boxer, PhD
- Email: gstt.hiya.pkd@nhs.net
- Phone: +44 20 7188 4770
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VX-407 pharmacokinetics after a single dose in adults with ADPKD
This study tests how VX-407 is absorbed, distributed, metabolized, and excreted after a one-time oral dose in adults with polycystic kidney disease.
-
How VX-407 interacts with common birth control pills
This study tests whether VX-407 affects how birth control pills work in people with ADPKD.
-
Renal embolization with EVOH for adults on dialysis with ADPKD
This study tests whether blocking blood flow to very large polycystic kidneys with the liquid embolic EVOH can shrink kidney size and reduce symptoms in adults on dialysis with ADPKD.
-
Ren-Nu: a kidney-focused ketogenic diet program for people with polycystic kidney disease
This 16-week pilot will try a dietitian-led, kidney-safe ketogenic program plus KetoCitra in adults with ADPKD to improve metabolic health.
-
Evaluating the safety of PYC-003 for treating a kidney disease
This study is testing a new drug called PYC-003 to see if it's safe for people with a specific type of kidney disease and healthy adults.
-
GV-100 first-in-human dose study in healthy adults
This early-stage study tests how GV-100 behaves and is tolerated in healthy adults to see how it might be used in people with ADPKD in the future.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.